SEC Form 4 · accession 0001638599-17-000159
ALBANY MOLECULAR RESEARCH INC · AMRI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven R Hagen
Officer — SVP Manufacturing & Pharmaceut
Period of report
Feb 4, 2017
Accepted (ET)
Feb 7, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001065087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2017 | F | 2,291 | $18.52 | D | 31,560 | D | |
| Common Stock | Feb 4, 2017 | F | 664 | $18.52 | D | 30,896 | D | |
| Common Stock | Feb 4, 2017 | F | 488 | $18.52 | D | 30,408 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person.